Mangoceuticals, INC. (MGRX) — 8-K Filings

All 8-K filings from Mangoceuticals, INC.. Browse 50 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (50)

MANGOCEUTICALS, INC. Files 8-K for Material Agreement — Dec 19, 2025 Risk: medium
On December 17, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company, incorporated in Texas with EIN 873841292, filed a Form 8-K
MANGOCEUTICALS, INC. Enters Material Definitive Agreement — Dec 10, 2025 Risk: medium
On December 4, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. This agreement also created a direct financial obligation or an obligati
8-K Filing — Nov 13, 2025
MANGOCEUTICALS, INC. Files 8-K with Multiple Agreements and Equity Changes — Oct 29, 2025 Risk: medium
On September 15, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement and also terminated a material definitive agreement. The company also c
MANGOCEUTICALS, INC. Files 8-K on Director Changes and Compensation — Sep 12, 2025 Risk: low
On September 9, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing a
MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — Sep 2, 2025 Risk: medium
On August 26, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
MANGOCEUTICALS, INC. Files 8-K with Key Agreements and Asset Changes — Aug 4, 2025 Risk: medium
On July 30, 2025, MANGOCEUTICALS, INC. reported the entry into a material definitive agreement, the termination of a material definitive agreement, and the comp
MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales — Jul 23, 2025 Risk: medium
On June 10, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and fi
MANGOCEUTICALS, INC. Files 8-K with Bylaw Amendments and Exhibits — Jul 10, 2025 Risk: low
On July 3, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing amendments to its articles of incorporation or bylaws and including financial statements and
MANGOCEUTICALS, INC. Reports Director and Officer Changes — Jul 3, 2025 Risk: medium
On July 1, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information on
MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — Jun 10, 2025 Risk: medium
On June 2, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose specific details regarding the number of
MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales — May 30, 2025 Risk: medium
On May 15, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and fil
Mangoceuticals Reports Material Agreements and Asset Changes — May 23, 2025 Risk: medium
On May 22, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing several material events. These include the entry into and termination of a material definiti
MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — May 6, 2025 Risk: medium
On April 28, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unreg
MANGOCEUTICALS, INC. Completes Acquisition, Announces Officer Changes — Apr 25, 2025 Risk: medium
On April 24, 2025, MANGOCEUTICALS, INC. reported the completion of an acquisition. The company also announced the departure of a director and the appointment of
MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Debt, Equity Sales — Apr 17, 2025 Risk: medium
On April 11, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation an
MANGOCEUTICALS, INC. Reports Board & Executive Changes — Apr 11, 2025 Risk: medium
On April 10, 2025, MANGOCEUTICALS, INC. reported changes in its board of directors and executive compensation. The filing details the departure of certain offic
MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — Apr 8, 2025 Risk: medium
On March 28, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose specific details regarding the number o
MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — Apr 2, 2025 Risk: medium
On March 28, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose specific details regarding the number o
MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — Mar 28, 2025 Risk: medium
On March 25, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The company, incorporated in Texas with its principal executive offi
MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — Mar 25, 2025 Risk: medium
On March 20, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and pro
MANGOCEUTICALS, INC. Files 8-K with Equity, Governance Updates — Mar 19, 2025 Risk: medium
On March 17, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing several key events. These include unregistered sales of equity securities, material modifi
MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — Feb 19, 2025 Risk: medium
On February 14, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
MANGOCEUTICALS, INC. Files 8-K Report — Feb 12, 2025 Risk: low
On February 12, 2025, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specifi
MANGOCEUTICALS, INC. Files 8-K: Equity Sales, Officer Changes, Financials — Feb 7, 2025 Risk: medium
On February 3, 2025, MANGOCEUTICALS, INC. reported on several key events. The company disclosed unregistered sales of equity securities and announced changes in
MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — Jan 31, 2025 Risk: medium
On January 27, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity sec
MANGOCEUTICALS, INC. Files 8-K: Agreements, Equity Sales, Officer Changes — Jan 21, 2025 Risk: medium
On January 15, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
MANGOCEUTICALS, INC. Files 8-K: Rights, Bylaws, and Financials Updated — Jan 15, 2025 Risk: low
On January 9, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing material modifications to the rights of its security holders. The filing also includes am
MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — Jan 8, 2025 Risk: medium
On December 31, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement, unregistered sales of equity securities, and financial
MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — Dec 26, 2024 Risk: medium
On December 18, 2024, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
MANGOCEUTICALS, INC. Completes Asset Acquisition, Discloses Equity Sales — Dec 19, 2024 Risk: medium
On December 13, 2024, MANGOCEUTICALS, INC. announced the completion of its acquisition of certain assets. The filing also disclosed unregistered sales of equity
MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales — Dec 6, 2024 Risk: medium
On December 2, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity sec
Mangoceuticals Adds Director, Discloses Officer Compensation — Nov 12, 2024 Risk: low
Mangoceuticals, Inc. announced on November 11, 2024, the election of Dr. David G. Smith as a new Class III Director, effective immediately. Dr. Smith brings ext
MANGOCEUTICALS, INC. Files 8-K Report — Oct 31, 2024 Risk: low
On October 30, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns other events and financial statements and exhibits. The company is
MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — Oct 25, 2024 Risk: medium
On October 18, 2024, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The company, incorporated in Texas with its principal executive of
MANGOCEUTICALS, INC. Enters Material Definitive Agreement — Oct 22, 2024 Risk: medium
On October 18, 2024, MANGOCEUTICALS, INC. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Tex
MANGOCEUTICALS, INC. Files 8-K Report — Oct 21, 2024 Risk: low
On October 21, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements
MANGOCEUTICALS, INC. Files 8-K on Security Holder Rights — Oct 11, 2024 Risk: low
On October 8, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing material modifications to security holder rights and other events. The company, incorpora
MANGOCEUTICALS, INC. Files 8-K Report — Oct 3, 2024 Risk: low
On October 3, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific
MANGOCEUTICALS, INC. Reports Unregistered Equity Sales — Oct 2, 2024 Risk: medium
On August 15, 2024, MANGOCEUTICALS, INC. reported unregistered sales of equity securities. The filing does not disclose specific details regarding the number of
MANGOCEUTICALS, INC. Files 8-K Report — Oct 1, 2024 Risk: low
On October 1, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mat
Mangoceuticals Reports Unregistered Equity Sale — Sep 27, 2024 Risk: medium
On September 26, 2024, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose the specific details of the sale, s
MANGOCEUTICALS, INC. Reports Equity Sale and Officer Changes — Aug 23, 2024 Risk: medium
On August 22, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing the unregistered sale of equity securities. The filing also announced changes in its boar
MANGOCEUTICALS, INC. Files 8-K on Financials — Aug 15, 2024 Risk: low
On August 14, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well
MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Financials — Jul 11, 2024 Risk: medium
On July 9, 2024, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported other events and filed financial statements and ex
MANGOCEUTICALS, INC. Files 8-K with Key Corporate Actions — Jul 2, 2024 Risk: medium
On April 26, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing several material events. These include entering into a material definitive agreement, unre
MANGOCEUTICALS, INC. Files 8-K on Security Holder Vote Matters — Jun 18, 2024 Risk: low
On June 17, 2024, MANGOCEUTICALS, INC. filed an 8-K report to announce the submission of matters to a vote of its security holders. The company, incorporated in
MANGOCEUTICALS, INC. Files 8-K: Equity Sales & Officer Changes — Jun 5, 2024 Risk: medium
On June 3, 2024, MANGOCEUTICALS, INC. reported on the unregistered sale of equity securities and changes in its board and officer composition. The company also
MANGOCEUTICALS, INC. Files 8-K on Listing Standards, Rights, and Bylaws — May 2, 2024 Risk: high
On April 29, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing several significant events. These include a notice of potential delisting or failure to me
MANGOCEUTICALS, INC. Files 8-K for Acquisition and Equity Events — Apr 25, 2024 Risk: medium
On April 19, 2024, MANGOCEUTICALS, INC. entered into a material definitive agreement related to the completion of an acquisition or disposition of assets. The c

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX